Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 Patients

By afschroeder • April 13, 2026

Valle LF, Romero-Kalbasi T, Jiang T, van Dams R, Fuller DB, Loblaw A, Kennedy T, Collins SP, Sharma V, Suy S, Murthy V, Mallick I, Nickols NG, Desai N, Hannan R, Aghdam N, Kaplan ID, Stephans K, Tendulkar R, Lau S, Taparra K, Steinberg ML, Kishan AU. Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 Patients. Eur Urol Oncol. 2026 Apr 10:S2588-9311(26)00078-7. doi: 10.1016/j.euo.2026.03.019. Epub ahead of print. PMID: 41966956.

Tags: DOM STAT, Dose escalation, General Internal Medicine, High-risk prostate cancer, hormone therapy, Publications, Radiotherapy, SBRT, Stereotactic body radiotherapy

Communicating Precision Medicine Research: Multidisciplinary Teams and Diverse Communities

Beans JA, Trinidad SB, Blacksher E, Hiratsuka VY, Spicer P, Woodahl EL, Boyer BB, Lewis CM Jr, Gaffney PM, Garrison NA, Burke W. Communicating Precision[...]

A Spanish-language educational intervention to enhance diabetes outcomes among existing continuous glucose monitor users in a federally qualified health care center

Tavares M, Khoshbin K, Solorzano W, Scarlett L, Santana C, Lopez R, Villanueva GP, Escobar B, Mangual KS, Pavlish C, Bush NJ, Moin T, Everett[...]

Lung Cancer Screening Centralization Is Associated With Improved Screening Uptake: The Veterans Healthcare Administration’s Experience 2015-2021

Benjamin LN, Núñez ER, Chen L, Motwani Y, Yuan A, Vangala S, Slatore CG, Wiener RS, Elashoff DA, Yano EM, Washington DL, Mangione CM. Lung[...]